MDR two years on: what the data tells us about readiness

The EU Medical Device Regulation has now been in force long enough to generate meaningful data about which organizations were genuinely prepared for its requirements and which were not. The patterns that have emerged are instructive — not just for organizations still navigating the transition, but for the broader question of how life sciences companies manage regulatory change.

The organizations that navigated MDR most effectively shared several characteristics. They started earlier than their peers. They treated MDR compliance as a portfolio management problem — systematically assessing their device portfolio against the new requirements, prioritizing remediation efforts based on revenue impact and strategic importance, and making explicit decisions about which legacy devices to certify and which to discontinue.

The organizations that struggled were those that treated MDR as a regulatory project rather than a strategic one. They focused on compliance processes without adequately addressing the portfolio-level questions: which devices are worth the investment required to certify them under the new framework? Which markets justify the cost? Which products should be rationalized?

The data on notified body capacity constraints, certification timelines, and the volume of devices that have been withdrawn from the EU market tells a clear story about the cost of underestimating the strategic dimensions of regulatory change.

For medical device organizations, the lesson is not primarily about regulatory compliance. It is about the importance of maintaining a portfolio view that can absorb and respond to regulatory change — treating it as one of several strategic variables that affect the value and viability of individual programs, rather than as an external constraint to be managed separately from portfolio strategy.